FACT SHEET

ABOUT CARDIOVASCULAR SYSTEMS, INC. NASDAQ: CSII

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a rapidly growing medical device company focused on developing and commercializing innovative solutions for treating vascular disease. The company’s Orbital Atherectomy Systems treat calcified plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. To date, more than 125,000 of CSI’s devices have been sold to leading institutions across the United States.

A NEW PATH THROUGH CORONARY CALCIUM

The FDA granted approval for use of the Diamondback 360® Coronary Orbital Atherectomy System on October 21, 2013. The 30-day data from CSI’s ORBIT II clinical study demonstrated that the Diamondback 360 Coronary OAS technology produced clinical outcomes that exceeded the trial’s two primary endpoints (safety and efficacy) by a significant margin. CSI is leading the industry with the Diamondback Revolution, a new movement providing innovative, evidence-based solutions that meet the demand for interventional cardiology treatments.

Coronary Artery Disease (CAD) is a life-threatening condition and leading cause of death in men and women in the United States. CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow. According to estimates, significant arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention (PCI). Significant calcium contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used, including a substantially higher occurrence of death and major adverse cardiac events (MACE).

FDA approval opens up a large, underserved U.S. market opportunity for CSI, estimated to exceed $1.5 billion annually.

The company began a controlled rollout in late October 2013. During the rollout, CSI is focusing on providing physicians with the quality experience to drive adoption in those accounts and will conduct post-market studies to enhance the company’s product offering and further build its body of clinical data.

FISCAL 2014 FIRST-QUARTER HIGHLIGHTS

- Revenues rose to $29.8 million, a 28-percent gain from $23.3 million in the first quarter of fiscal 2013.
- Customer reorder revenues remained strong at 96 percent of total revenue.
- Company received coronary FDA approval, market size estimated at $1.5 billion in the U.S.
- Controlled launch of Diamondback 360 Coronary Orbital Atherectomy System has begun.

FINANCIAL SUMMARY

As of Oct. 31, 2013

| Ticker: CSII | Price Per Share: $30.34 |
| Shares Outstanding: 24.90 million | Market Cap: $755.62 million |
| Exchange: NASDAQ Global |

Analyst Coverage

Ben Andrew, William Blair & Company
Danielle Antalffy, Leerink Swann
Jose Haresco, JMP Securities
Ben Haynor, Feltl and Company
Brooks O’Neil, Dougherty & Company
James Terwilliger, Wunderlich Securities
Jan Wald, The Benchmark Company
Edward White, Laidlaw & Company

REVENUES (in millions)

<table>
<thead>
<tr>
<th>Quarter</th>
<th>2014 Total</th>
<th>2013 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 2014</td>
<td>$29.8</td>
<td>$23.3</td>
</tr>
<tr>
<td>Q1 2013</td>
<td>$22.4</td>
<td>$18.5</td>
</tr>
</tbody>
</table>

QUARTERLY STEALTH 360® REVENUES (in millions)

<table>
<thead>
<tr>
<th>Quarter</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 2014</td>
<td>$25.9</td>
<td></td>
</tr>
<tr>
<td>Q1 2013</td>
<td>$18.5</td>
<td></td>
</tr>
</tbody>
</table>

Certain statements in this fact sheet are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act.
PERIPHERAL ARTERIAL DISEASE: AN UNDERSERVED, GROWING MARKET

PAD is a common circulatory disease where plaque deposits build up on the walls of blood vessels, reducing blood flow. PAD affects more than 12 percent of the U.S. population over age 65. Plaque ranges from soft to calcified. Calcified and fibrotic deposits are the most difficult to treat with traditional interventional procedures and are more common in older patients. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.

COMMITTED TO CLINICAL DATA

ORBIT II

CSI presented 30-day results from its ORBIT II study of coronary artery disease in late-breaking presentations at the 2013 European Association of Percutaneous Cardiovascular Interventions (EuroPCR) conference in Paris, and the 2013 Complex Cardiovascular Catheter Therapeutics (C3) conference in Orlando, Florida. Results showed that 92.8 percent of patients were free from severe angiographic complications, and core lab assessed final procedure residual stenosis was 4.7 percent.

Dr. Jeffrey Chambers of Metropolitan Heart and Vascular Institute, Minneapolis, highlighted data showing that at 30 days, patient freedom from major adverse cardiac events, or MACE, was 89.6 percent and procedural success was 88.9 percent (including in hospital MACE). Patients had less than 50 percent residual stenosis 98.6 percent of the time, and 97.7 percent of stents were successfully delivered.

LIBERTY 360°

During the fiscal 2013 first quarter, CSI continued enrolling patients in its post-market study, LIBERTY 360°. The study is evaluating the acute and long-term clinical and economic outcomes of the company’s orbital atherectomy system in treating PAD. It is the first study of its kind to compare orbital atherectomy to all other PAD interventional treatment options in a difficult-to-treat patient population. As a prospective, observational, multi-center post-market study, LIBERTY 360° will enroll up to 1,200 patients at 100 sites across the United States, including 500 patients with claudication (painful circulatory problems), 500 who suffer from critical limb ischemia (a severe form of PAD) and 200 scheduled for amputation.